79695206/02/201413/05/2015DraftDraft23/09/202017/10/2017Gaelle Chételathttp://admin-epid-prod2.inserm.fr/content/view/full/83246http://admin-epid-prod2.inserm.fr/content/view/full/87571http://admin-epid-prod2.inserm.fr/ccontent/xml/(NodeId)/83246Etude longitudinale en imagerie multimodale de la maladie d'Alzheimer à un stade précoce: biomarqueurs de détection et de progression et mécanismes physiopathologiquesLongitudinal Study on Multimodal Imaging for Early-Stage Alzheimer's Disease: Biomarkers for Detection and Progression and Physiopathological Mechanisms IMAP+IMAP+ CNIL:1238252 ; CPP 2011-A01493-38CNIL:1238252; CPP 2011-A01493-38NeurologiePsychologie et psychiatrieNeurologyPsychology and psychiatryGénétiqueMode de vie et comportementsGeneticLifestyle and behaviorGénétiquemaladie d'Alzheimerdiagnostic précocevieillissement normalactivation cérébraleTEPIRMIRMfneuro-anatomiebiomarqueursimagerie moléculaireAV45TEP-FDGactimétriepolysomnographiestyle de viesommeilqualité de vieneuropsychologieGeneticsearly diagnosisnormal ageingneuroimagingPETMRIfMRIneuroanatomymolecular imagingFDG-PETAlzheimer's diseasebiomarkersAV45ChételatGaëlCHU Côte de Nacre Bd Henri Becquerel, BP 5229, 14033 CAEN +33 (0)2 31 47 01 73chetelat@cyceron.frU1077/ U1237 U1077: Institut national de la santé et de la recherche médicale - Inserm ; CHU Caen ; Université de Caen ; U1237:INSERM, EFS, Univ. Caen-NormandieChételatGaëlCHU Côte de Nacre Bd Henri Becquerel, BP 5229, 14033 CAEN +33 (0)2 31 47 01 73chetelat@cyceron.frU1077/ U1237 U1077: Institut national de la santé et de la recherche médicale - Inserm ; CHU Caen ; Université de Caen ; U1237:INSERM, EFS, Univ. Caen-NormandieOuiYesNational collaborations • IMAP – IMAP+ projects: L Barré (Centre Cyceron, Caen ; TEP tracers), D Vivien & Carine Ali (Centre Cyceron, Caen ; tPA dosage); D Guilloteau (Tours; molecular neuroimaging); F Pasquier (Lille, recruiting center), D Hannequin (Rouen, genetic mutation) • Connectivity project (funded by Fondation Plan Alzheimer): Marc Dhenain (MIRCen UMR9199, Paris) • Meditageing European H2020 project: A Lutz (Inserm, Lyon, France) & P Krolak Salmon (Hospices Civils de Lyon, France) European collaborations • Meditageing European H2020 project: F Colette & E Salmon (University of Liege, Belgium), N Marchant (University College London, UK), F Jessen (University of Cologne, Germany), O Klimecki, P Vuilleumier and P Sanders (The University of Geneva, Switzerland), Jose-Luis Molinuevo (Hospital Clínic/IDIBAPS, Spain). • DTI and hippocampal subfields in Alzheimer’s disease. Andreas Fellgiebel (Department of Psychiatry and Psychotherapy, Johannes Gutenberg-University of Mainz, Germany)  has led to 1 publication • Collaborative research project on connectivity: E Salmon (Belgium) & I Yakushev (Germany) & A Fellgiebel  has led to 4 publications • EMIF-AD: a large shared database for biomarkers in AD International collaborations • William Jagust, Jagust Lab (UC Berkeley Helen Wills Neuroscience Institute, UC Berkeley School of Public Health, the Lawrence Berkeley National Laboratory, USA): twinned lab and collaborative project on Lifestyle. My team has built a collaboration over a number of years with the Jagust Lab in Berkeley. This has started by sharing of personnel, and has progressively grown into a series of regular intercontinental “virtual laboratory meetings”. Approximately once every 2 months, the two labs have a joint lab meeting using Skype to videoconference, with presentations from scientists at each lab. Over time this has supported the development of similar interests and the desire to pursue a research program jointly. Based on previous work by both groups, we have decided that we can productively collaborate in the investigation of lifestyle effects on the brain, and therefore we applied to the France Berkeley Fund, which we were granted for, for a joint project on lifestyle. • Amyloid and tau imaging: Victor Villemagne & Christopher Rowe (Department of Nuclear medicine and Centre for PET/ University of Melbourne/ Austin health, Victoria, Australia)  has led to 15 publications • Collaborative international project on Alzheimer disease patients with an amyloid-negative PET scan leaded by G Chételat: Gil Rabinovici (UCLA San Francisco, US), Victor Villemagne (Melbourne, Australia) and Philip Scheltens (Amsterdam)  has led to 1 publication in Brain (Chételat et al., in press). • The Amyloid PET Study Group (e.g. Ossenkoppele et al.; JAMA Neurol, 2015) National and international networks • SCD (Subjective Cognitive Decline) international initiative  has led to 2 publications in Alzheimers Dement and J Alzheimers Dis. • HS3 (Hippocampal subfield international collaborative project)  has led to 1 publication in Neuroimage. • EANM (European Association of Nuclear Medicine)  has led to 1 publication in Eur J Nucl Med Mol Imaging. • Neuroimaging Professional Interest Area (NIPIA) of the Alzheimer’s Association’s International Society to Advance Alzheimer Research and Treatment (ISTAART)  has led to 1 publication in Neurology. • The Amyloid PET Study Group  has led to 2 publications in JAMA. • CATI Consortium (Centre d'Acquisition et de Traitement d'Images pour la maladie d'Alzheimer)  has led to 1 publication in Neuroinformatics. • “Reserve, Resilience and Protective Factors” Professional Interest Area of the Alzheimer’s Association’s International Society to Advance Alzheimer Research and Treatment (ISTAART)PubliquePublicAssociation France Alzheimer, Fondation Plan Alzheimer (Alzheimer Plan 2008-2012), Programme Hospitalier de Recherche Clinique (PHRC National 2011 et 2012), Agence Nationale de la Recherche (ANR LONGVIE 2007), Région Basse-Normandie, Institut National de la Santé et de la Recherche Médicale) (Inserm).French Alzheimer's Association, Alzheimer's Foundation Plan [Fondation Plan Alzheimer] (Alzheimer's Plan 2008-2012), Hospital Clinical Research Programme (ANR LONGVIE 2007), Lower-Normandy Region, French National Institute of Health and Medical Research (INSERM)CHU Caen Secteur PublicCHU Caen Secteur PublicBases de données issues d’enquêtesStudy databasesEtudes longitudinales (hors cohortes)Longitudinal study (except cohorts)Via une sélection de services ou établissements de santéVia un fichier de populationA selection of health institutions and servicesA population fileNonNoLes sujets sains seront recrutés à partir d'annonces passées dans des journaux locaux, sur des sites web, à l'occasion de conférences mais aussi déposées et/ou distribuées dans des lieux publics ou via le bouche à oreille. Après avoir été recrutés, ils seront invités à se rendre dans les centres investigateurs (Lille et Caen) pour la visite de sélection. Les sujets NORMA seront recrutés par l'intermédiaire d'un courrier envoyé aux neurologues de la métropole française ayant diagnostiqué une forme familiale de MA pour lesquels les résultats attestant d'une mutation causale ont été établis. Les personnes répondant aux critères de sélection seront incluses dans l'étude. Les analyses génétiques seront réalisées à Rouen tandis que tous les autres examens seront réalisés à Caen. Les patients SCI, MCI, MA et SAND seront quant à eux recrutés aux seins des services de neurologie ou des centres de consultation mémoire des différents centres de recrutement (CHU de Caen, Rennes, Rouen, Lille, Tours, Alençon, Lisieux et Cherbourg). A la visite d'inclusion ainsi qu'aux suivantes, il leur sera conseillé qu'une personne de leur entourage les accompagne. Cette personne nommée "accompagnant" devra être assez proche du patient et bien le connaître, c'est-à-dire passer au moins une journée par semaine avec lui (conjoint, famille, voisin ou ami) car des questions lui seront posées pour mieux cerner ses troubles. Dans la mesure du possible, cette personne devra être la même pendant toute l'étude. Seules des questions sur les troubles de mémoire du patient, ses habitudes et ses activités quotidiennes lui seront posées. 280 sujets/patients à inclure: - 40 sujets sains contrôles jeunes (18-39 ans) - 40 sujets sains contrôles d'âge intermédiaire (40-59 ans) - 40 sujets sains contrôles âgés (à partir de 60 ans) - 50 NORMA (NORMaux apparentés) - 40 patients avec déficits cognitifs subjectifs (Subjectives Cognitive Impairment) - 40 patients avec déficits cognitifs légers (Mild Cognitive Impairment - MCI) - 30 patients atteints de maladie d'Alzheimer probable (MA) - 15 patients atteints d'un syndrome amnésique non neurodégénératif (SAND)Healthy subjects will be recruited from advertisements in local newspapers, on websites, during conferences, as well as posting and/or distribution in public places or through word of mouth. Subjects will be invited to attend research centres for the screening visit following recruitment. NORMA subjects will be recruited through correspondence sent to neurologists from the French capital, having been diagnosed with familial AD where results demonstrating causal mutation were established. Individuals that meet the selection criteria will be included in the study. Genetic analyses will be performed in Rouen and all other tests will be conducted in Caen. SCI, MCI, MA and SAND patients will be recruited from neurology departments or memory assessment services across various recruitment centres (CHU in Caen, Rennes, Rouen, Lille and Tours). Individuals should be accompanied by someone they know at baseline and subsequent visits. This person, referred to as the "accompanying party" should be quite close to the patient and know them well, i.e. spends at least one day per week with them (spouse, family member, neighbour or friend), as they will be asked questions to better identify disorders. This person should be the same where possible. Only questions regarding the patient's memory disorders, habits and daily activities will be asked. 280 subjects/patients to be included: - 40 young healthy control subjects (18-39 years old) - 40 middle-aged healthy control subjects (40-59 years old) - 40 elderly healthy control subjects (aged 60+) - 50 NORMA subjects (NORMaux Apparentés) - 40 patients with subjective cognitive impairment - 40 patients with mild cognitive impairment (Mild Cognitive Impairment - MCI) - 30 patients with probable Alzheimer's disease (AD) - 15 patients with amnesic syndrome that is not neurodegenerative (SAND).Objectif général: Étudier et comparer l'efficacité de différents marqueurs in vivo pour prédire le déclin cognitif chez des populations à risque de développer la maladie d'Alzheimer au moyen de mesures de neuroimagerie, de neuropsychologie et de biologie. Objectifs secondaires : Étudier i) Les profils d'altération des sujets NORMA et des patients SCI, MCI, MA et SAND par rapport aux sujets sains du même âge; ii) Les profils d'altération des porteurs de l'allèle E4 de l'apolipoprotéine E (ApoE4) par rapport aux non porteurs; iii) Les modifications cérébrales et cognitives au cours du vieillissement normal ; iv) L'évolution et la dynamique de ces différents biomarqueurs au cours du suivi. Étudier les liens entre les différents profils d'altération (comparaisons et corrélations intra-modalité), ainsi que les différences inter-groupes des profils d'évolutionGeneral objective: To study and compare the effectiveness of different in vivo markers to predict cognitive decline in patients at risk of developing Alzheimer's disease through neuroimaging, neuropsychology and biology measures. Secondary objectives: To study: i) Deterioration in NORMA subjects, as well as SCI, MCI, AD and SAND patients compared with healthy subjects of the same age; ii) Deterioration in E4 allele and apolipoprotein E (ApoE) carriers compared to non-carriers; iii) Cerebral and cognitive changes during normal ageing; iv) Progress and dynamics of different biomarkers during follow-up. To study the links between different deterioration profiles (intra-modality comparison and correlation), as well as differences in inter-group progression profiles.Niveau d’étude supérieur ou égal à 7 ans, langue maternelle français, signature du consentement éclairé, examens médical, neurologique, neuroradiologique et batterie neuropsychologique diagnostique. Sujets contrôles : performances normales selon l'âge et le niveau d'éducation à tous les tests de la batterie diagnostique. Intermédiaire (40-59 ans) : sans plainte mnésique. Âgés (+60ans) : vie à domicile, autonome, sans plainte mnésique. NORMA (+18ans) apparentés à un malade identifié, porteurs d’un des gènes mutés associés à la forme familiale à début précoce de la MA, avec performances normales selon l’âge et le niveau d’éducation à tous les tests de la batterie diagnostique. Patients des centres de consultation mémoire: SCI (+50ans) avec plainte mnésique, performances dans les normes pour l’âge et le niveau d’éducation à tous les tests de la batterie diagnostique. MCI répondant aux critères actuels de MCI amnésique avec plainte mnésique, déficits objectifs de la mémoire épisodique, performances dans les autres fonctions cognitives que la mémoire pouvant être déficitaires, indépendants dans la vie quotidienne, absence de syndrome démentiel selon les critères du DSM-IV et absence de MA probable selon les critères du NINCDS-ADRDA. Patients Alzheimer répondant aux critères standards du NINCDS-ADRDA de MA probable avec fonctionnement cognitif global anormal et déficits dans au moins 2 domaines cognitifs mis en évidence par la batterie diagnostique, dans un stade léger à modéré de MA et signature du consentement éclairé du protocole par son accompagnant. SAND : services de neurologie des CHU - trouble massif de la mémoire épisodique, pouvant être associé à un déficit objectif des fonctions exécutives et des performances dans les normes pour l’âge et le niveau d’éducation à tous les tests de la batterie diagnostique mesurant les fonctions instrumentales.Education level equal to 7 years or higher, native language is French, signed informed consent, medical, neurological and neuroimaging tests, as well as neuropsychological diagnostic test battery. Control subjects: normal performance according to age and education level in all diagnostic battery tests. Middle-aged (40-59 years old): no memory complaints. Elderly (aged 60+): living at home, independent, no memory complaints. NORMA (aged 18+) with identified disease, carriers of mutated gene associated with familial early-onset AD, normal performance according to age and education level in all diagnostic battery tests. Patients from memory assessment centres: SCI (aged 50+), no memory complaints, normal performance according to age and education level in all diagnostic battery tests. MCI meeting current amnestic MCI criteria with memory complaints, objective episodic memory deficits, performances in other cognitive functions where memory loss could occur, standard performance for age and education level in assessments of overall cognitive ability, independent in everyday life, no dementia according to DSM-IV criteria and no probable AD according to NINCDS-ADRDA criteria. Alzheimer's patients meeting NINCDS-ADRDA criteria for probable AD with abnormal overall cognitive function and deficits in at least 2 cognitive areas identified by diagnostic battery tests; mild- to moderate-stage AD; accompanying party's signed informed consent. SAND: CHU neurology departments - major episodic memory disorder that may be related to an objective deficit in executive function and standard performance for age and education level in all diagnostic battery tests measuring instrumental function.Adulte (19 à 24 ans)Adulte (25 à 44 ans)Adulte (45 à 64 ans)Personnes âgées (65 à 79 ans)Grand âge (80 ans et plus)Adulthood (19 to 24 years)Adulthood (25 to 44 years)Adulthood (45 to 64 years)Elderly (65 to 79 years)Great age (80 years and more)Sujets maladesSick populationG30 - Maladie d'AlzheimerF00.-G30 - Alzheimer diseaseMasculinFémininMaleWomanNationalNationalLes 3/4 des patients viennent de la région. Région Nord (centre investigateur de Lille) et région Nord Ouest (centre investigateur de Caen)3/4 of patients are from the region.2012201220192019< 500 individus< 500 individuals280280Collecte des données activeCurrent data collectionDonnées cliniquesDonnées déclarativesDonnées paracliniquesDonnées biologiquesDonnées administrativesClinical dataDeclarative dataParaclinical dataBiological dataAdministrative dataDossier cliniqueExamen médicalDirect physical measuresMedical registrationLes données cliniques recueillies par l'intermédiaire du dossier clinique ne concernent que les patients SCI, MCI, MA et SANDClinical data collected through clinical records only include SCI, MCI, AD and SAND patients.Auto-questionnaire papierFace à faceTéléphonePaper self-questionnaireFace to face interviewPhone interviewTest neuropsychologiques incluant des auto-questionnaires, en entretien en face à face, mais aussi par téléphone pour la prise de contact.Neuropsychological tests include self-administered questionnaires, face-to-face interview and initial contact by phone.Imagerie: IRM anatomique, IRM fonctionnelle au repos, IRM fonctionnelle d’activation, TEP-FDG et TEP-AV-45, sommeil (actimétrie et polysomnographie)Imaging: Anatomical MRI, fMRI at rest, active fMRI, FDG-PET and PET AV-45Éléments biologiques (sanguins et du LCR):i) dosage sanguin des marqueurs de la fibrinolyse (tPA, ADAMTS-4);ii) dosages sanguins l'AB40 et AB42 et dans le LCR de l'AB40, AB42, de la protéine tau et de sa forme phosphorylée,iii) génotypage du gène de l'ApoE;iv) séquençage du gène potentiellement muté pour les sujets NORMABiological components (blood and CSF): i) blood test for fibrinolysis markers (tPA, ADAMTS-4); ii) AB40 and AB42 blood tests and AB40, AB42 CSF, tau protein and its phosphorylated form, iii) ApoE genotyping; iv) potential mutated gene sequencing in NORMA subjectsEtat civil, âge, sexe, langue maternelle, niveau d'étudeCivil status, sex, native language, education levelOuiYesPlasmaAutres fluides (salive, urine, liquide amniotique, …)ADNPlasmaFluids (saliva, urine, amniotic fluid, …)DNAPlasma, ADN et LCR conservés à -80°CComponents stored at -80°C.Evénements de santé/morbiditéQualité de vie/santé perçueHealth event/morbidityQuality of life/health perceptionqualité de vie évaluée à l'aide d'auto-questionnairesVenue des sujets/patients pour 6 examens d'environ 2h + une prise de sang+enregistrement d'actimétrie sur 1 semaine+ 1 nuit de polysomnographie en ambulatoire+une ponction lombaire (facultative). L'ensemble de ces examens est réalisé sur un délai d'environ 1 mois. Les sujets/patients sont pris en charge par une personne référente qui les suit et les accompagne tout au long du protocole.Subjects/patients attend 6 examinations lasting approx. 2 hours + one blood sample. All examinations are conducted over a period of approx. 1 month. Subjects/patients are treated by a contact person that monitors and supports them throughout the protocol. Collected data are reviewed in a multimodal meeting. Imaging data quality control results are also reported during this meeting. Collected data are reviewed during a diagnostic commission so that subject/patient results, as well as their enrolment category, can be reported on a case-by-case basis.NINCDS-ADRDA et DSM IVNINCDS-ADRDA and DSM IVUne commission de diagnostique est organisée mensuellement afin de faire un point, au cas par cas, sur les résultats neuropsychologiques des sujets/patients, ainsi que leur catégorie d'inclusion. La qualité des données est évaluée lors de réunion multimodalités. Lors de cette réunion mensuelle, les résultats du contrôle qualité de l'ensemble des données (neuroimagerie, neuropsychologie et sommeil) sont rapportés.Un Attaché de Recherche Clinique mandaté par le CHU, assure le monitoring de cet essai, afin de garantir le recueil de données exactes, complètes et fiables, ainsi qu'une aide logistique aux centre investigateurs.A diagnostic commission is organised on a monthly basis to report subject/patient neuropsychological results, as well as their enrolment category, on a case-by-case basis. A multimodal meeting is organised on a monthly basis to report quality control results for imaging data. This trial is monitored by a person appointed by the CHU to ensure that exact, complete and reliable data is collected and to provide logistical support to research centres.OuiYesSuivi par contact avec le participant (lettre, e-mail, téléphone etc.)Suivi par convocation du participantSuivi par contact avec le médecin référent – traitantMonitoring by contact with the participant (mail, e-mail, telephone etc.)Monitoring by convocation of the participantMonitoring by contact with the referring doctorSuivi de 36 mois pour les sujets âgés sains, les patients SCI et MCI uniquement si les données d'imagerie acquises à l'inclusion et /ou à la visite 18 mois post inclusion ne sont pas exploitables. Suivi de 18 mois pour les sujets jeunes, intermédiaires et les patients MA. A l'issue des 18 mois post-inclusion de suivi, tous les participants (à l'exception des NORMA), seront à nouveau invités à réaliser, de manière quasi identique, l'ensemble des examens proposés à l'inclusion: une évaluation neuropsychologique détaillée, un prélèvement sanguin (sans génotypage), 2 sessions IRM, un examen TEP-FDG au repos, un examen TEP-AV45, un enregistrement du sommeil par actimétrie d'une semaine. A l'issue des 36 mois post-inclusion de suivi, les sujets âgés sains, et les patients SCI et MCI, seront à nouveau invités à réaliser, de manière identique à celle décrite pour la visite des 18 mois. Dans le cas où les données à l'inclusion et à 18 mois post-inclusion sont de bonne qualité (évaluation de la qualité de celles-ci lors des réunions multimodalités), le suivi à 36 mois post-inclusion ne sera réalisé qu'en partie n'incluant que des évaluations neuropsychologiques.Elderly healthy subjects, NORMA subjects, as well as SCI and MCI patients are monitored over a period of 36 months Young, middle-aged and AD patients are monitored over a period of 18 months Post-monitoring enrolment after 18 months; all participants will be asked to take all of the baseline tests again in an almost identical fashion: detailed neuropsychological evaluation, blood sample (without genotyping), 2 MRI sessions, FDG-PET at rest and PET-AV45 test. Post-monitoring enrolment after 36 months, elderly healthy subjects, NORMA subjects, as well as SCI and MCI patients will be asked to take the same tests as described for the visit at 18 months.G30 - Maladie d'AlzheimerF00.-G30 - Alzheimer diseaseNonNohttps://www.ncbi.nlm.nih.gov/pubmed/28764930Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation. Arenaza-Urquijo EMhttps://www.ncbi.nlm.nih.gov/pubmed/28653793 Intrinsic connectivity of hippocampal subfields in normal elderly and mild cognitive impairment patients. de Flores Rhttps://www.ncbi.nlm.nih.gov/pubmed/28054025Qualitative and quantitative assessment of self-reported cognitive difficulties in nondemented elders: Association with medical help seeking, cognitive deficits, and β-amyloid imaging. La Joie Rhttps://www.ncbi.nlm.nih.gov/pubmed/27693187Subjective cognitive decline in cognitively normal elders from the community or from a memory clinic: Differential affective and imaging correlates. Perrotin Ahttps://www.ncbi.nlm.nih.gov/pubmed/27357349Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. Chételat Ghttps://www.ncbi.nlm.nih.gov/pubmed/27103523Relationships between sleep quality and brain volume, metabolism, and amyloid deposition in late adulthood. Branger Phttps://www.ncbi.nlm.nih.gov/pubmed/26106572Brain structural, functional, and cognitive correlates of recent versus remote autobiographical memories in amnestic Mild Cognitive Impairment. Tomadesso Chttps://www.ncbi.nlm.nih.gov/pubmed/28066167Connectivity Disruption, Atrophy, and Hypometabolism within Posterior Cingulate Networks in Alzheimer's Disease. Mutlu Jhttps://www.ncbi.nlm.nih.gov/pubmed/27683850Relative effect of APOE ε4 on neuroimaging biomarker changes across the lifespan. Gonneaud Jhttps://www.ncbi.nlm.nih.gov/pubmed/23670109Reply: The amyloid cascade is not the only pathway to AD. Chételat G.https://www.ncbi.nlm.nih.gov/pubmed/24656258Intrinsic connectivity identifies the hippocampus as a main crossroad between Alzheimer's and semantic dementia-targeted networks. La Joie Rhttps://www.ncbi.nlm.nih.gov/pubmed/29668866Distinct Interplay Between Atrophy and Hypometabolism in Alzheimer's Versus Semantic Dementia.https://www.ncbi.nlm.nih.gov/pubmed/29203090Regional patterns of gray matter volume, hypometabolism, and beta-amyloid in groups at risk of Alzheimer's disease.https://www.ncbi.nlm.nih.gov/pubmed/29780872Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment patients.https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/30784816Is there a specific memory signature associated with Aβ-PET positivity in patients with amnestic mild cognitive impairment? Tomadesso Chttps://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/30788411Brain and cognitive correlates of sleep fragmentation in elderly subjects with and without cognitive deficits. André Chttps://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/31286994Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time. Kuhn Ehttps://pubmed.ncbi.nlm.nih.gov/32122680/[White matter hyperintensities in ageing: Pathophysiology, associated cognitive disorders and prevention]. Garnier-Crussard Ahttps://pubmed.ncbi.nlm.nih.gov/30060016/Which is to blame for cognitive decline in ageing: amyloid deposition, neurodegeneration or both?. Gonneaud Jhttps://pubmed.ncbi.nlm.nih.gov/29150540/Increased florbetapir binding in the temporal neocortex from age 20 to 60 years. Gonneaud Jhttps://pubmed.ncbi.nlm.nih.gov/29046365/Amyloid PET scan: Staging beyond reading?. Chételat Ghttps://pubmed.ncbi.nlm.nih.gov/29194503/Distinct influence of specific versus global connectivity on the different Alzheimer's disease biomarkers. Mutlu Jhttps://pubmed.ncbi.nlm.nih.gov/28860449/Reduced age-associated brain changes in expert meditators: a multimodal neuroimaging pilot study. Chételat Ghttps://pubmed.ncbi.nlm.nih.gov/29504542/Multimodal Neuroimaging in Alzheimer's Disease: Early Diagnosis, Physiopathological Mechanisms, and Impact of Lifestyle. Chételat Ghttps://pubmed.ncbi.nlm.nih.gov/28035923/Neural Correlates of Self-Reference Effect in Early Alzheimer's Disease. Gaubert Mhttps://pubmed.ncbi.nlm.nih.gov/27981671/Distinct white matter injury associated with medial temporal lobe atrophy in Alzheimer's versus semantic dementia. Bejanin Ahttps://pubmed.ncbi.nlm.nih.gov/26998659/Distinct neural substrates of affective and cognitive theory of mind impairment in semantic dementia. Bejanin Ahttps://pubmed.ncbi.nlm.nih.gov/27757821/Distinct effects of late adulthood cognitive and physical activities on gray matter volume. Arenaza-Urquijo EMhttps://pubmed.ncbi.nlm.nih.gov/26827785/Neuroimaging biomarkers in Alzheimer's disease and other dementias. Villemagne VLhttps://pubmed.ncbi.nlm.nih.gov/26691733/Self-reference effect on memory in healthy aging, mild cognitive impairment and Alzheimer's disease: Influence of identity valence. Leblond Mhttps://pubmed.ncbi.nlm.nih.gov/26306871/Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease. De Flores Rhttps://pubmed.ncbi.nlm.nih.gov/26321944/Cognitive reserve and lifestyle: moving towards preclinical Alzheimer's disease. Arenaza-Urquijo EMhttps://pubmed.ncbi.nlm.nih.gov/26402076/Hippocampal Subfield Volumetry and 3D Surface Mapping in Subjective Cognitive Decline. Perrotin Ahttps://pubmed.ncbi.nlm.nih.gov/25231681/Effects of age and Alzheimer's disease on hippocampal subfields: comparison between manual and FreeSurfer volumetry. De Flores Rhttps://pubmed.ncbi.nlm.nih.gov/26203136/Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease. Besson FLhttps://pubmed.ncbi.nlm.nih.gov/26408498/Interaction between years of education and APOE ε4 status on frontal and temporal metabolism. Arenaza-Urquijo EMhttps://pubmed.ncbi.nlm.nih.gov/26085009/Anosognosia in Alzheimer disease: Disconnection between memory and self-related brain networks. Perrotin Ahttps://pubmed.ncbi.nlm.nih.gov/25146994/Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan. Fouquet Mhttps://pubmed.ncbi.nlm.nih.gov/24179789/Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Chételat Ghttps://pubmed.ncbi.nlm.nih.gov/24179859/Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia. La Joie Rhttps://pubmed.ncbi.nlm.nih.gov/23084083/Age effect on the default mode network, inner thoughts, and cognitive abilities. Mevel Khttps://pubmed.ncbi.nlm.nih.gov/23518010/Relationships between brain metabolism decrease in normal aging and changes in structural and functional connectivity. Chételat Ghttps://pubmed.ncbi.nlm.nih.gov/23796547/Relationships between years of education and gray matter volume, metabolism and functional connectivity in healthy elders. Arenaza-Urquijo EMhttps://pubmed.ncbi.nlm.nih.gov/23399647/Alzheimer disease: Aβ-independent processes-rethinking preclinical AD. Chételat Ghttps://pubmed.ncbi.nlm.nih.gov/23152610/Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. La Joie Rhttps://pubmed.ncbi.nlm.nih.gov/22119654/Role of hippocampal CA1 atrophy in memory encoding deficits in amnestic Mild Cognitive Impairment. Fouquet Mhttps://pubmed.ncbi.nlm.nih.gov/22628162/Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Villain Nhttps://pubmed.ncbi.nlm.nih.gov/21752148/Which SPM method should be used to extract hippocampal measures in early Alzheimer's disease?. Mevel Khttps://pubmed.ncbi.nlm.nih.gov/21760988/The default mode network in healthy aging and Alzheimer's disease. Mevel Khttps://pubmed.ncbi.nlm.nih.gov/20331499/A simple way to improve anatomical mapping of functional brain imaging. Villain Nhttps://pubmed.ncbi.nlm.nih.gov/20688814/Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Villain Nhttps://pubmed.ncbi.nlm.nih.gov/20600996/Differential effect of age on hippocampal subfields assessed using a new high-resolution 3T MR sequence. La Joie Rhttps://pubmed.ncbi.nlm.nih.gov/22557957/When Higher Activations Reflect Lower Deactivations: A PET Study in Alzheimer's Disease during Encoding and Retrieval in Episodic Memory. Bejanin Ahttps://www.ncbi.nlm.nih.gov/pubmed/28764930https://www.ncbi.nlm.nih.gov/pubmed/28653793 https://www.ncbi.nlm.nih.gov/pubmed/28054025https://www.ncbi.nlm.nih.gov/pubmed/27693187https://www.ncbi.nlm.nih.gov/pubmed/27357349https://www.ncbi.nlm.nih.gov/pubmed/27103523https://www.ncbi.nlm.nih.gov/pubmed/26106572https://www.ncbi.nlm.nih.gov/pubmed/28066167https://www.ncbi.nlm.nih.gov/pubmed/27683850https://www.ncbi.nlm.nih.gov/pubmed/23670109https://www.ncbi.nlm.nih.gov/pubmed/24656258https://www.ncbi.nlm.nih.gov/pubmed/29668866https://www.ncbi.nlm.nih.gov/pubmed/29203090https://www.ncbi.nlm.nih.gov/pubmed/29780872https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/30784816https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/30788411https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/31286994https://pubmed.ncbi.nlm.nih.gov/32122680/https://pubmed.ncbi.nlm.nih.gov/30060016/https://pubmed.ncbi.nlm.nih.gov/29150540/https://pubmed.ncbi.nlm.nih.gov/29046365/https://pubmed.ncbi.nlm.nih.gov/29194503/https://pubmed.ncbi.nlm.nih.gov/28860449/https://pubmed.ncbi.nlm.nih.gov/29504542/https://pubmed.ncbi.nlm.nih.gov/28035923/https://pubmed.ncbi.nlm.nih.gov/27981671/https://pubmed.ncbi.nlm.nih.gov/26998659/https://pubmed.ncbi.nlm.nih.gov/27757821/https://pubmed.ncbi.nlm.nih.gov/26827785/https://pubmed.ncbi.nlm.nih.gov/26691733/https://pubmed.ncbi.nlm.nih.gov/26306871/https://pubmed.ncbi.nlm.nih.gov/26321944/https://pubmed.ncbi.nlm.nih.gov/26402076/https://pubmed.ncbi.nlm.nih.gov/25231681/https://pubmed.ncbi.nlm.nih.gov/26203136/https://pubmed.ncbi.nlm.nih.gov/26408498/https://pubmed.ncbi.nlm.nih.gov/26085009/https://pubmed.ncbi.nlm.nih.gov/25146994/https://pubmed.ncbi.nlm.nih.gov/24179789/https://pubmed.ncbi.nlm.nih.gov/24179859/https://pubmed.ncbi.nlm.nih.gov/23084083/https://pubmed.ncbi.nlm.nih.gov/23518010/https://pubmed.ncbi.nlm.nih.gov/23796547/https://pubmed.ncbi.nlm.nih.gov/23399647/https://pubmed.ncbi.nlm.nih.gov/23152610/https://pubmed.ncbi.nlm.nih.gov/22119654/https://pubmed.ncbi.nlm.nih.gov/22628162/https://pubmed.ncbi.nlm.nih.gov/21752148/https://pubmed.ncbi.nlm.nih.gov/21760988/https://pubmed.ncbi.nlm.nih.gov/20331499/https://pubmed.ncbi.nlm.nih.gov/20688814/https://pubmed.ncbi.nlm.nih.gov/20600996/https://pubmed.ncbi.nlm.nih.gov/22557957/http://www.gael-chetelat.fr/?page_id=81http://www.gael-chetelat.fr/?page_id=81Publications Modalités d'accès à la base de données en cours de définitionPublications. Database access conditions are currently being determined.Accès restreint sur projet spécifiqueAccess on specific project onlyAccès restreint sur projet spécifiqueAccess on specific project only